Possibility of non-invasive diagnostics of liver fibrosis in patients after chemotherapy with normal weight and overweight
According to the World Health Organization, diseases of the gastrointestinal tract rank third place after cardiovascular disease and cancer and more than 2 billion people suffer from hepatic diseases and toxic hepatitis is one of them. Given the complexity of differentiation and confirmation of iatrogenic toxic hepatitis and broad spectrum of possible medication side effects, there is a real problem with precise statistics of hepatic drug lesions. This study aims to improve the possibility of diagnosing liver fibrosis in patients with normal weight and overweight and determine and study the relationship between the level of polyfunctional cytokine TGF-β1 with BMI. We examined 44 patients with a history of breast cancer of I-II degree according to the TNM classification (TNM-8 system, 2016) without malignancy and who belonged to the III clinical group (persons with proven malignant tumors who have completed radical treatment and are in remission) aged 35 to 79 years. Patients were divided into two main groups. The first group included patients without signs of toxic liver disease and the second group represented patients with signs of toxic hepatitis. In addition to biochemical analysis, the subjects were examined to determine the FibroTest index to verify the fibrosis stage. Additionally, the FIB-4 index was calculated. This study found that FIB-4 and fibrotest may be sensitive and reliable methods for liver fibrosis screening in patients after cancer chemotherapy. The presence of excess body weight may be an important factor in predicting the development of severe fibrosis in such patients. The level of profibrogenic cytokine TGF-β1 may be an additional predictor of fibrosis progression.